|
| ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines |
|
https://doi.org/10.18632/oncotarget.28551
Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay, Bryan W. Day, Brett W. Stringer, and Paul A. Tooney
|
| 1-18 |
|
| Retraction: Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.28366
Sijie Cheng, Tieling Li, Cheng Wang, Keyu Wang, Chengcai Lai, Jin Yan, Hongxia Fan, Fang Sun, Zhaohai Wang, Peirui Zhang, Linxiang Yu, Zhixian Hong, Guanglin Lei, Baijun Sun, Yuan Gao, Zhaohui Xiao, Xu Ji, Ruilan Wang, Jianzhong Wu, Xiliang Wang, Shaogeng Zhang, and Penghui Yang
|
| 19-19 |
|
| Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma |
|
https://doi.org/10.18632/oncotarget.28548
Bilal M. El-Masri, Benedeta Leka, Fatima Mustapha, Michael Tveden Gundesen, Maja Hinge, Thomas Lund, Thomas L. Andersen, Marta Diaz-delCastillo, and Abbas Jafari
|
| 20-26 |
|
| Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report |
|
https://doi.org/10.18632/oncotarget.28550
Shreya Bhatia, Manuel G. Cortez, Spencer Lessans, and Wade T. Iams
|
| 27-30 |
|
| The fate of drug discovery in academia; dumping in the publication landfill? |
|
https://doi.org/10.18632/oncotarget.28552
Uzma Saqib, Isaac S. Demaree, Alexander G. Obukhov, Mirza S. Baig, Amiram Ariel, and Krishnan Hajela
|
| 31-34 |
|
| Retraction: Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice |
|
https://doi.org/10.18632/oncotarget.28532
Fariba Poosti, Ruchi Bansal, Saleh Yazdani, Jai Prakash, Leonie Beljaars, Jacob van den Born, Martin H. de Borst, Harry van Goor, Jan-Luuk Hillebrands, and Klaas Poelstra
|
| 35-35 |
|
| Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation |
|
https://doi.org/10.18632/oncotarget.28544
Mark Lee, and Luc GT Morris
|
| 36-48 |
|
| BCAS1 defines a heterogeneous cell population in diffuse gliomas |
|
https://doi.org/10.18632/oncotarget.28553
Raquel Morales-Gallel, María José Ulloa-Navas, Patricia García-Tárraga, Ricardo Prat-Acín, Gaspar Reynés, Pedro Pérez-Borredá, Luis Rubio, Vivian Capilla-González, Jaime Ferrer-Lozano, and José Manuel García-Verdugo
|
| 49-64 |
|
| Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.28547
Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson
|
| 65-75 |
|
| Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples |
|
https://doi.org/10.18632/oncotarget.28554
Chongtham Sovachandra Singh, Nabamita Boruah, Atanu Banerjee, Sillarine Kurkalang, Pooja Swargiary, Hughbert Dakhar, and Anupam Chatterjee
|
| 76-89 |
|
| Retraction: Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX |
|
https://doi.org/10.18632/oncotarget.28462
Huan Liu, Guizhi Zhou, Xin Fu, Haiyan Cui, Guangrui Pu, Yao Xiao, Wei Sun, Xinhua Dong, Libin Zhang, Sijia Cao, Guiqin Li, Xiaowei Wu, and Xu Yang
|
| 90-90 |
|
| Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis |
|
https://doi.org/10.18632/oncotarget.28512
P.A. Shatalov, N.A. Falaleeva, E.A. Bykova, D.O. Korostin, V.A. Belova, A.A. Zabolotneva, A.P. Shinkarkina, A. Yu Gorbachev, M.B. Potievskiy, V.S. Surkova, Zh V. Khailova, N.A. Kulemin, Denis Baranovskii, A.A. Kostin, A.D. Kaprin, and P.V. Shegai
|
| 91-103 |
|
| Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells |
|
https://doi.org/10.18632/oncotarget.28536
Yunfei Liao, Lulu Chen, Yong Feng, Jacson Shen, Yan Gao, Gregory Cote, Edwin Choy, David Harmon, Henry Mankin, Francis Hornicek, and Zhenfeng Duan
|
| 104-105 |
|
| Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland |
|
https://doi.org/10.18632/oncotarget.28555
Wei Zhang, Arndt A. Schmitz, Roosa E. Kallionpää, Merja Perälä, Niina Pitkänen, Mikko Tukiainen, Erika Alanne, Korinna Jöhrens, Renate Schulze-Rath, Bahman Farahmand, and Jihong Zong
|
| 106-116 |
|
| Combining causal and correlative approaches to discover biomarkers of response to paclitaxel |
|
https://doi.org/10.18632/oncotarget.28549
Alberto Moscona-Nissan, Karl J. Habashy, Victor A. Arrieta, Adam M. Sonabend, and Crismita Dmello
|
| 117-122 |
|
| Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy |
|
https://doi.org/10.18632/oncotarget.28560
Changhwan Yoon, Kevin K. Chang, Jun Ho Lee, William D. Tap, Charles P. Hart, M. Celeste Simon, and Sam S. Yoon
|
| 123-123 |
|
| GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells |
|
https://doi.org/10.18632/oncotarget.28557
Michael R. Booth, Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent
|
| 124-133 |
|
| Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health |
|
https://doi.org/10.18632/oncotarget.28561
Elisabetta De Matteis, Maria Rosaria Tumolo, Paolo Tarantino, Mariangela Ciccarese, Tiziana Grassi, Francesco Bagordo, Maria Rita De Giorgio, Emanuele Rizzo, and Graziana Ronzino
|
| 134-141 |
|
| Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.28523
Maryam Zanjirband, Nicola Curtin, Richard J. Edmondson, and John Lunec
|
| 142-142 |
|
| Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model |
|
https://doi.org/10.18632/oncotarget.28524
Tsion Zewdu Minas, Jenny Han, Tahereh Javaheri, Sung-Hyeok Hong, Michaela Schlederer, Yasemin Saygideğer-Kont, Haydar Çelik, Kristina M. Mueller, Idil Temel, Metin Özdemirli, Heinrich Kovar, Hayriye Verda Erkizan, Jeffrey Toretsky, Lukas Kenner, Richard Moriggl, and Aykut Üren
|
| 143-143 |
|
| Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas |
|
https://doi.org/10.18632/oncotarget.28559
Thomas M. Cardillo, Maria B. Zalath, Roberto Arrojo, Robert M. Sharkey, Serengulam V. Govindan, Chien-Hsing Chang, and David M. Goldenberg
|
| 144-158 |
|
| GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells |
|
https://doi.org/10.18632/oncotarget.28558
Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent
|
| 159-174 |
|
| G-quadruplex landscape and its regulation revealed by a new antibody capture method |
|
https://doi.org/10.18632/oncotarget.28564
Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama Ghosh, Akanksha Mudgal, Divyesh Patel, Thenmalarchelvi Rathinavelan, and Umashankar Singh
|
| 175-198 |
|
| Correction: Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma |
|
https://doi.org/10.18632/oncotarget.28519
Lucia Longhitano, Carlo Castruccio Castracani, Daniele Tibullo, Roberto Avola, Maria Viola, Giuliano Russo, Orazio Prezzavento, Agostino Marrazzo, Emanuele Amata, Michele Reibaldi, Antonio Longo, Andrea Russo, Nunziatina Laura Parrinello, and Giovanni Li Volti
|
| 199-199 |
|
| Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay |
|
https://doi.org/10.18632/oncotarget.28565
Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang, Shuyuan Ma, Tina X. Chen, Janet Lai, Nitin Udar, Juan-Sebastian Saldivar, Erin Ayash, Joshua Anderson, Jiang Li, Tiange Cui, Tu Le, Ruthie Chow, Randy Jerel Velasco, Chris Mallo, Rose Santiago, Robert C. Bruce, Laurie J. Goodman, Yi Chen, Dan Norton, Richard O. Chen, and John M. Lyle
|
| 200-218 |
|
| Retraction: PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/β-catenin signaling pathway |
|
https://doi.org/10.18632/oncotarget.28522
Huijun Gao, Bing Sun, Hailu Fu, Xinming Chi, Faming Wang, Xiaoyu Qi, Jun Hu, and Shujuan Shao
|
| 219-219 |
|
| ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells |
|
https://doi.org/10.18632/oncotarget.28563
Benigno C. Valdez, Bin Yuan, David Murray, Jeremy L. Ramdial, Uday Popat, Yago Nieto, and Borje S. Andersson
|
| 220-231 |
|
| From osimertinib to preemptive combinations |
|
https://doi.org/10.18632/oncotarget.28569
Mikhail V. Blagosklonny
|
| 232-237 |
|
| Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer |
|
https://doi.org/10.18632/oncotarget.28567
Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, Elizabeth A. Mittendorf, and Jennifer K. Litton
|
| 238-247 |
|
| Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.28579
Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally, and Joaquin J. Jimenez
|
| 248-254 |
|
| Retraction: Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e |
|
https://doi.org/10.18632/oncotarget.28568
Wei Gong, Jian Zheng, Xiaobai Liu, Jun Ma, Yunhui Liu, and Yixue Xue
|
| 255-255 |
|
| Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface |
|
https://doi.org/10.18632/oncotarget.28578
Takahiro Ohashi, Sayuri Terada, Shinsuke Hiramoto, Yuko Nagata, Hirokazu Suzuki, Hitoshi Miyashita, Tetsuo Sasaki, Yasukatsu Tsukada, and Keiko Fukushima
|
| 256-274 |
|
| Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure |
|
https://doi.org/10.18632/oncotarget.28582
Shengliang Zhang, and Wafik S. El-Deiry
|
| 275-284 |
|
| Correction: Gap junction-mediated transfer of miR-145-5p from microvascular endothelial cells to colon cancer cells inhibits angiogenesis |
|
https://doi.org/10.18632/oncotarget.28528
Dominique Thuringer, Gaetan Jego, Kevin Berthenet, Arlette Hammann, Eric Solary, and Carmen Garrido
|
| 285-287 |
|
| Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN |
|
https://doi.org/10.18632/oncotarget.28583
Kevin C. Ma, Esther Mena, Liza Lindenberg, Nathan S. Lay, Phillip Eclarinal, Deborah E. Citrin, Peter A. Pinto, Bradford J. Wood, William L. Dahut, James L. Gulley, Ravi A. Madan, Peter L. Choyke, Ismail Baris Turkbey, and Stephanie A. Harmon
|
| 288-300 |
|
| Retraction: Chronically high level of tgfb1a induction causes both hepatocellular carcinoma and cholangiocarcinoma via a dominant Erk pathway in zebrafish |
|
https://doi.org/10.18632/oncotarget.28570
Chuan Yan, Qiqi Yang, Han-Ming Shen, Jan M. Spitsbergen, and Zhiyuan Gong
|
| 301-301 |
|
| Cyclin D1 expression in penile cancer |
|
https://doi.org/10.18632/oncotarget.28584
Wesliany Everton Duarte, Jaqueline Diniz Pinho, Syomara Pereira da Costa Melo, Denner Rodrigo Diniz Duarte, Juliana Martins da Guia Ribeiro do Carmo, André Salim Khayat, José Ribamar Rodrigues Calixto, Marcos Adriano Garcia Campos, Rita da Graça Carvalhal Frazão Correa, Antonio Machado Alencar Júnior, Antônio Augusto Lima Teixeira-Júnior, and Gyl Eanes Barros Silva
|
| 302-311 |
|
| Retraction: Knockdown of TRIM65 inhibits lung cancer cell proliferation, migration and invasion: A therapeutic target in human lung cancer |
|
https://doi.org/10.18632/oncotarget.28571
Xiao-Lin Wang, Wei-Ping Shi, Hong-Can Shi, Shi-Chun Lu, Kang Wang, Chao Sun, Jian-Sheng He, Wei-Guo Jin, Xiao-Xia Lv, Hui Zou, and Yu-Sheng Shu
|
| 312-312 |
|
| The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response |
|
https://doi.org/10.18632/oncotarget.28585
Lulzim Shkreta, Johanne Toutant, Aurélie Delannoy, David Durantel, Anna Salvetti, Sophie Ehresmann, Martin Sauvageau, Julien A. Delbrouck, Alice Gravel-Trudeau, Christian Comeau, Caroline Huard, Jasmin Coulombe-Huntington, Mike Tyers, David Grierson, Pierre-Luc Boudreault, and Benoit Chabot
|
| 313-325 |
|
| Correction: Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription of srebp1 |
|
https://doi.org/10.18632/oncotarget.28562
Jun Guo, Weiwei Fang, Libo Sun, Yonggang Lu, Lin Dou, Xiuqing Huang, Mingxiao Sun, Cheng Pang, Jing Qu, Guanghui Liu, and Jian Li
|
| 326-327 |
|
| GZ17-6.02 kills PDX isolates of uveal melanoma |
|
https://doi.org/10.18632/oncotarget.28586
Laurence Booth, Jane L. Roberts, Ivan Spasojevic, Kaitlyn C. Baker, Andrew Poklepovic, Cameron West, John M. Kirkwood, and Paul Dent
|
| 328-344 |
|
| The importance of integrated therapies on cancer: Silibinin, an old and new molecule |
|
https://doi.org/10.18632/oncotarget.28587
Elisa Roca, Giuseppe Colloca, Fiorella Lombardo, Andrea Bellieni, Alessandra Cucinella, Giorgio Madonia, Licia Martinelli, Maria Elisa Damiani, Ilaria Zampieri, and Antonio Santo
|
| 345-353 |
|
| Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma |
|
https://doi.org/10.18632/oncotarget.28580
Mohammad Krayem, Ahmad Najem, Fabrice Journe, Renato Morandini, François Sales, Ahmad Awada, and Ghanem E. Ghanem
|
| 354-354 |
|
| Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification |
|
https://doi.org/10.18632/oncotarget.28589
Jai N. Patel, Jai Singh, and Nilanjan Ghosh
|
| 355-359 |
|
| Retraction: Long non-coding RNA H19 induces hippocampal neuronal apoptosis via Wnt signaling in a streptozotocin-induced rat model of diabetes mellitus |
|
https://doi.org/10.18632/oncotarget.28576
Yu-Hao Zhao, Tie-Feng Ji, Qi Luo, and Jin-Lu Yu
|
| 360-360 |
|
| Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy |
|
https://doi.org/10.18632/oncotarget.28588
Benigno C. Valdez, Apostolia M. Tsimberidou, Bin Yuan, Yago Nieto, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen, and Borje S. Andersson
|
| 361-373 |
|
| When does a melanoma metastasize? Implications for management |
|
https://doi.org/10.18632/oncotarget.28591
John F. Thompson, and Gabrielle J. Williams
|
| 374-378 |
|
| Correction: FOXC1 promotes melanoma by activating MST1R/PI3K/AKT pathway and is associated with poor prognosis in melanoma |
|
https://doi.org/10.18632/oncotarget.28590
Jinhua Wang, Li Li, Shiwei Liu, Ying Zhao, Lin Wang, and Guanhua Du
|
| 379-380 |
|
| Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management |
|
https://doi.org/10.18632/oncotarget.28566
Scott Strum, Mark Vincent, Meghan Gipson, Eric McArthur, and Daniel Breadner
|
| 381-388 |
|
| Leveraging gold nanostars for precision laser interstitial thermal therapy |
|
https://doi.org/10.18632/oncotarget.28592
Aden P. Haskell-Mendoza, Ethan S. Srinivasan, Tuan Vo-Dinh, and Peter E. Fecci
|
| 389-391 |
|
| Starving cancer cells to enhance DNA damage and immunotherapy response |
|
https://doi.org/10.18632/oncotarget.28595
Aashirwad Shahi, and Dawit Kidane
|
| 392-399 |
|
| Genomics has more to reveal |
|
https://doi.org/10.18632/oncotarget.28596
Laurène Fenwarth, and Nicolas Duployez
|
| 400-401 |
|
| Retraction: Hypoxia-inducible factor 1a induces phenotype switch of human aortic vascular smooth muscle cell through PI3K/AKT/AEG-1 signaling |
|
https://doi.org/10.18632/oncotarget.28575
Kai Liu, Changcun Fang, Yuwen Shen, Zhengqin Liu, Min Zhang, Bingbing Ma, and Xinyan Pang
|
| 402-402 |
|
| Targeting ABC transporters in PDAC – past, present, or future? |
|
https://doi.org/10.18632/oncotarget.28597
Cecilia Bergonzini, Elisa Giovannetti, and Erik H.J. Danen
|
| 403-406 |
|
| Correction: Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay |
|
https://doi.org/10.18632/oncotarget.28581
Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang, Shuyuan Ma, Tina X. Chen, Janet Lai, Nitin Udar, Juan-Sebastian Saldivar, Erin Ayash, Joshua Anderson, Jiang Li, Tiange Cui, Tu Le, Ruthie Chow, Randy Jerel Velasco, Chris Mallo, Rose Santiago, Robert C. Bruce, Laurie J. Goodman, Yi Chen, Dan Norton, Richard O. Chen, and John M. Lyle
|
| 407-407 |
|
| Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma |
|
https://doi.org/10.18632/oncotarget.28594
Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, and Koichiro Yamakado
|
| 408-417 |
|
| HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity |
|
https://doi.org/10.18632/oncotarget.28598
Marcus Schmidt, Hans-Anton Lehr, and Katrin Almstedt
|
| 418-420 |
|
| Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer |
|
https://doi.org/10.18632/oncotarget.28599
S.H. Tolmeijer, E. Boerrigter, N.P. Van Erp, and Niven Mehra
|
| 421-423 |
|
| Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status |
|
https://doi.org/10.18632/oncotarget.28602
Jun Zhang, Lanlan Zhou, Shuai Zhao, and Wafik S. El-Deiry
|
| 424-438 |
|
| Correction: BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV |
|
https://doi.org/10.18632/oncotarget.28600
Anne K. Barasa, Peng Ye, Meredith Phelps, Ganapathiram T. Arivudainambi, Timelia Tison, and Javier Gordon Ogembo
|
| 439-440 |
|
| Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.28556
Dae Won Kim, Francisca Beato, Youngchul Kim, Alexandra F. Tassielli, Ruifan Dai, Jason W. Denbo, Pamela J. Hodul, Mokenge P. Malafa, and Jason B. Fleming
|
| 441-441 |
|
| DDX41 and its unique contribution to myeloid leukemogenesis |
|
https://doi.org/10.18632/oncotarget.28603
Hirotaka Matsui
|
| 442-443 |
|
| Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.28605
Alexandra Jackovich, Barbara J. Gitlitz, Justin Wayne Wong Tiu-lim, Vinay Duddalwar, Kevin George King, Anthony B. El-Khoueiry, Jacob Stephen Thomas, Denice Tsao-Wei, David I. Quinn, Parkash S. Gill, and Jorge J. Nieva
|
| 444-458 |
|
| Genotype matters: Personalized screening recommendations for germline CHEK2 variants |
|
https://doi.org/10.18632/oncotarget.28604
Adela Rodriguez Hernandez, Rochelle Scheib, Judy E. Garber, Huma Q. Rana, and Brittany L. Bychkovsky
|
| 459-460 |
|
| Retraction: Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models |
|
https://doi.org/10.18632/oncotarget.28601
Chrysovalantou Mihailidou, Pavlos Papakotoulas, Athanasios G. Papavassiliou, and Michalis V. Karamouzis
|
| 461-461 |
|
| The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy |
|
https://doi.org/10.18632/oncotarget.28607
Maria Gracia-Hernandez, Manasa Suresh, and Alejandro Villagra
|
| 462-465 |
|
| How to deal with runaway metastatic disease? |
|
https://doi.org/10.18632/oncotarget.28609
Justine Paris, and Guilhem Bousquet
|
| 466-467 |
|
| Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics |
|
https://doi.org/10.18632/oncotarget.28593
Gaurav S. Choudhary, Trinh T. Tat, Saurav Misra, Brian T. Hill, Mitchell R. Smith, Alexandru Almasan, and Suparna Mazumder
|
| 468-469 |
|
| INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death |
|
https://doi.org/10.18632/oncotarget.28608
Chantal L. Duurland, Thijs de Gunst, Harm C. den Boer, Marion T.J. van den Bosch, Bryony J. Telford, Rogier M. Vos, Xiaolei Xie, Mingfa Zang, Fang Wang, Yingying Shao, Xiaoyu An, Jingjing Wang, Jie Cai, Ludovic Bourré, Laurens A.H. van Pinxteren, Roel Q.J. Schaapveld, Michel Janicot, and Sanaz Yahyanejad
|
| 470-485 |
|
| Targeting the multifaceted BRAF in cancer: New directions |
|
https://doi.org/10.18632/oncotarget.28612
Eamon Toye, Alexander Chehrazi-Raffle, Justin Hwang, and Emmanuel S. Antonarakis
|
| 486-492 |
|
| Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors |
|
https://doi.org/10.18632/oncotarget.28606
Kseniya Sinichenkova, Iliya Sidorov, Nataliya Kriventsova, Dmitriy Konovalov, Ruslan Abasov, Nataliya Usman, Alexander Karachunskiy, Galina Novichkova, Dmitriy Litvinov, and Alexander Druy
|
| 493-500 |
|
| Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity |
|
https://doi.org/10.18632/oncotarget.28610
Jack G. Fisher, Lara V. Graham, and Matthew D. Blunt
|
| 501-503 |
|
| Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.28527
Yiyao Zhang, Li Liu, Pei Fan, Nathalie Bauer, Jury Gladkich, Eduard Ryschich, Alexandr V. Bazhin, Nathalia A. Giese, Oliver Strobel, Thilo Hackert, Ulf Hinz, Wolfgang Gross, Franco Fortunato, and Ingrid Herr
|
| 504-506 |
|
| Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma |
|
https://doi.org/10.18632/oncotarget.28615
Caroline Naomi Valdez, Gabriela Athziri Sánchez-Zuno, Lais Osmani, Wael Ibrahim, Anjela Galan, Antonietta Bacchiocchi, Ruth Halaban, Rajan P. Kulkarni, Insoo Kang, Richard Bucala, and Thuy Tran
|
| 507-520 |
|
| Prevalence and impact of the KIT M541L variant in patients with mastocytosis |
|
https://doi.org/10.18632/oncotarget.28614
Luisa N. Dominguez Aldama, Eric Karlins, Xiaoping Sun, Daniel Veltri, Hirsh D. Komarow, Irina Maric, Dean D. Metcalfe, and Melody C. Carter
|
| 521-531 |
|
| Beyond pixels: Graph filtration learning unveils new dimensions in hepatocellular carcinoma imaging |
|
https://doi.org/10.18632/oncotarget.28635
Yashbir Singh
|
| 532-534 |
|
| Targeting WNT5B and WNT10B in osteosarcoma |
|
https://doi.org/10.18632/oncotarget.28617
Gustavo A. Miranda-Carboni, and Susan A. Krum
|
| 535-540 |
|
| Retraction: Berberine and cinnamaldehyde together prevent lung carcinogenesis |
|
https://doi.org/10.18632/oncotarget.28577
Mingjing Meng, Shengnan Geng, Zhenhua Du, Jingjing Yao, Yaqiu Zheng, Zibo Li, Zhenzhen Zhang, Jiahuan Li, Yongjian Duan, and Gangjun Du
|
| 541-541 |
|
| Retraction: CUL4B promotes bladder cancer metastasis and induces epithelial-to-mesenchymal transition by activating the Wnt/β-catenin signaling pathway |
|
https://doi.org/10.18632/oncotarget.28407
Xia-Wa Mao, Jia-Quan Xiao, Gang Xu, Zhong-Yi Li, Hui-Feng Wu, Yi Li, Yi-Chun Zheng, and Nan Zhang
|
| 542-542 |
|
| Next-generation vaccines are showing promise against glioblastoma |
|
https://doi.org/10.18632/oncotarget.28636
Robert O. Dillman, and Daniela A. Bota
|
| 543-548 |
|
| Retraction: IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.28573
Chuanzong Zhao, Qian Wang, Ben Wang, Qi Sun, Zhaobin He, Jianguo Hong, Florian Kuehn, Enyu Liu, and Zongli Zhang
|
| 549-549 |
|
| Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival |
|
https://doi.org/10.18632/oncotarget.28633
Saif Zaman, Fred S. Gorelick, Andrea Chrobrutskiy, Boris I. Chobrutskiy, Gary V. Desir, and George Blanck
|
| 550-561 |
|
| The gut barrier as a gatekeeper in colorectal cancer treatment |
|
https://doi.org/10.18632/oncotarget.28634
Roy Hajjar, Carole Richard, and Manuela M. Santos
|
| 562-572 |
|
| Retraction: The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer |
|
https://doi.org/10.18632/oncotarget.28431
Hong Wang, Chunlei Wang, Wenling Tian, and Yanfen Yao
|
| 573-573 |
|
| Retraction: In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway |
|
https://doi.org/10.18632/oncotarget.28616
Ling-Yu Kong, Mei Xue, Qing-Cai Zhang, and Chuan-Fu Su
|
| 574-574 |
|
| A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice |
|
https://doi.org/10.18632/oncotarget.28638
Zhen Li, Mohammed A. Alshagawi, Rebecca A. Oot, Mariam K. Alamoudi, Kevin Su, Wenhui Li, Michael P. Collins, Stephan Wilkens, and Michael Forgac
|
| 575-587 |
|
| Artificial intelligence: A transformative tool in precision oncology |
|
https://doi.org/10.18632/oncotarget.28639
Jeremy McGale, Matthew J. Liao, Egesta Lopci, Aurélien Marabelle, and Laurent Dercle
|
| 588-589 |
|
| Retraction: MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1 |
|
https://doi.org/10.18632/oncotarget.28645
Ling Xiao, Hui Zhou, Xiang-Ping Li, Juan Chen, Chao Fang, Chen-Xue Mao, Jia-Jia Cui, Wei Zhang, Hong-Hao Zhou, Ji-Ye Yin, and Zhao-Qian Liu
|
| 590-590 |
|
| Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties |
|
https://doi.org/10.18632/oncotarget.28641
Alan Halim, Nasreen Al-Qadi, Elizabeth Kenyon, Kayla N. Conner, Sujan Kumar Mondal, Zdravka Medarova, and Anna Moore
|
| 591-606 |
|
| Generative AI in oncological imaging: Revolutionizing cancer detection and diagnosis |
|
https://doi.org/10.18632/oncotarget.28640
Yashbir Singh, Quincy A. Hathaway, and Bradley J. Erickson
|
| 607-608 |
|
| Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche |
|
https://doi.org/10.18632/oncotarget.28642
Ding-Wen Chen, Eric K. Wafula, and Peter Kurre
|
| 609-613 |
|
| Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics |
|
https://doi.org/10.18632/oncotarget.28637
Xiaobing Tian, and Wafik S. El-Deiry
|
| 614-633 |
|
| Retraction: Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer |
|
https://doi.org/10.18632/oncotarget.28649
Fei Song, Hong Wang, and Yingying Wang
|
| 634-634 |
|
| The emerging role of AI in enhancing intratumoral immunotherapy care |
|
https://doi.org/10.18632/oncotarget.28643
Abin Sajan, Abdallah Lamane, Asad Baig, Korentin Le Floch, and Laurent Dercle
|
| 635-637 |
|
| Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors |
|
https://doi.org/10.18632/oncotarget.28650
Joshua J. Lingo, Ellen Voigt, and Dawn E. Quelle
|
| 638-643 |
|
| UBA1 dysfunction in VEXAS and cancer |
|
https://doi.org/10.18632/oncotarget.28646
Maki Sakuma, Torsten Haferlach, and Wencke Walter
|
| 644-658 |
|
| Retraction: Association study of inflammatory cytokine and chemokine expression in hand foot and mouth disease |
|
https://doi.org/10.18632/oncotarget.28655
Wenzhong Shang, Suying Qian, Lijuan Fang, Yong Han, and Cuiping Zheng
|
| 659-659 |
|
| Lessons from the ACDC-RP trial: Clinical trial design for radical prostatectomy neoadjuvant therapy trials |
|
https://doi.org/10.18632/oncotarget.28648
Rashid K. Sayyid, and Neil E. Fleshner
|
| 660-661 |
|
| Zika virus and brain cancer: Can Zika be an effective treatment for brain cancer? A systematic review |
|
https://doi.org/10.18632/oncotarget.28647
Mateus Gonçalves de Sena Barbosa, Beatriz Rodrigues Messias, Rafael Trindade Tatit, Maycon Cristian Gomes de Paula, Valdecir Boeno Spenazato Júnior, Maria Gabriella Borges Braga, Caio Vinícius Marcolino Santos, Luiza D'Ottaviano Cobos, Vinícius Otávio da Silva, Eberval Gadelha Figueiredo, Nicollas Nunes Rabelo, and Bipin Chaurasia
|
| 662-673 |
|
| Transplant or no transplant for TP53 mutated AML |
|
https://doi.org/10.18632/oncotarget.28652
Talha Badar, Moazzam Shahzad, Ehab Atallah, Mark R. Litzow, and Mohamed A. Kharfan-Dabaja
|
| 674-676 |
|
| Correction: Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer |
|
https://doi.org/10.18632/oncotarget.28656
Chengfei Liu, Cameron Armstrong, Yezi Zhu, Wei Lou, and Allen C. Gao
|
| 677-678 |
|
| Molecular chaperones: Guardians of tumor suppressor stability and function |
|
https://doi.org/10.18632/oncotarget.28653
Jennifer A. Heritz, Sarah J. Backe,, and Mehdi Mollapour
|
| 679-696 |
|
| Correction: Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin |
|
https://doi.org/10.18632/oncotarget.28657
Simone Buraschi, Shi-Qiong Xu, Manuela Stefanello, Igor Moskalev, Alaide Morcavallo, Marco Genua, Ryuta Tanimoto, Ruth Birbe, Stephen C. Peiper, Leonard G. Gomella, Antonino Belfiore, Peter C. Black, Renato V. Iozzo, and Andrea Morrione
|
| 697-698 |
|
| Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition |
|
https://doi.org/10.18632/oncotarget.28651
Madison Rackear, Elias Quijano, Zaira Ianniello, Daniel A. Colón-Ríos, Adam Krysztofiak, Rashed Abdullah, Yanfeng Liu, Faye A. Rogers, Dale L. Ludwig, Rohini Dwivedi, Franziska Bleichert, and Peter M. Glazer
|
| 699-713 |
|
| Gene regulatory network and signalling pathway rewiring: How blood cancer cells shift their shapes to evade drug treatment |
|
https://doi.org/10.18632/oncotarget.28662
Constanze Bonifer, and Peter N. Cockerill
|
| 714-716 |
|
| Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor |
|
https://doi.org/10.18632/oncotarget.28654
Marta Arregui, Antonio Calles, María del Mar Galera, Ana Gutiérrez, Carlos López-Jiménez, Carolina Agra, Adriana Fernández, Natalia Gutiérrez, María de Toro, and Rosa Álvarez
|
| 717-724 |
|
| Retraction: Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma |
|
https://doi.org/10.18632/oncotarget.28663
Valerie B. Sampson, Nancy S. Vetter, Wendong Zhang, Pratima U. Patil, Robert W. Mason, Erika George, Richard Gorlick, and Edward A. Kolb
|
| 725-725 |
|
| Initiation of tumor dormancy by the lymphovascular embolus |
|
https://doi.org/10.18632/oncotarget.28658
Yin Ye, Justin Wang, Michael G. Izban, Billy R. Ballard, and Sanford H. Barsky
|
| 726-740 |
|
| A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy |
|
https://doi.org/10.18632/oncotarget.28659
Murtaza Ahmed, Brent K. Larson, Arsen Osipov, Nilofer Azad, and Andrew Hendifar
|
| 741-747 |
|
| Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation |
|
https://doi.org/10.18632/oncotarget.28664
Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Christel Larbouret, Marie-Alix Poul, Philippe Mondon, Gerry Melino, André Pèlegrin, and Thierry Chardès
|
| 748-749 |
|
| Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC |
|
https://doi.org/10.18632/oncotarget.28660
Samuel Silva, Juliana C. Sousa, Cleto Nogueira, Raquel Feijo, Francisco Martins Neto, Laura Cardoso Marinho, Guilherme Sousa, Valeria Denninghoff, and Fabio Tavora
|
| 750-763 |
|
| Beyond the hype: Navigating bias in AI-driven cancer detection |
|
https://doi.org/10.18632/oncotarget.28665
Yashbir Singh, Heenaben Patel, Diana V. Vera-Garcia, Quincy A. Hathaway, Deepa Sarkar, and Emilio Quaia
|
| 764-766 |
|
| Retraction: MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4 |
|
https://doi.org/10.18632/oncotarget.28669
Dantong Cheng, Senlin Zhao, Huamei Tang, Dongyuan Zhang, Hongcheng Sun, Fudong Yu, Weiliang Jiang, Ben Yue, Jingtao Wang, Meng Zhang, Yang Yu, Xisheng Liu, Xiaofeng Sun, Zongguang Zhou, Xuebin Qin, Xin Zhang, Dongwang Yan, Yugang Wen, and Zhihai Peng
|
| 767-767 |
|
| Understanding the interplay between extracellular matrix topology and tumor-immune interactions: Challenges and opportunities |
|
https://doi.org/10.18632/oncotarget.28666
Yijia Fan, Alvis Chiu, Feng Zhao, and Jason T. George
|
| 768-781 |
|
| Mitigating bias in radiology: The promise of topological data analysis and simplicial complexes |
|
https://doi.org/10.18632/oncotarget.28668
Yashbir Singh, Colleen Farrelly, Quincy A. Hathaway, and Gunnar Carlsson
|
| 782-783 |
|
| Persistence barcodes: A novel approach to reducing bias in radiological analysis |
|
https://doi.org/10.18632/oncotarget.28667
Yashbir Singh, Colleen Farrelly, Quincy A. Hathaway, and Gunnar Carlsson
|
| 784-786 |
|
| Visualizing radiological data bias through persistence images |
|
https://doi.org/10.18632/oncotarget.28670
Yashbir Singh, Colleen Farrelly, Quincy A. Hathaway, and Gunnar Carlsson
|
| 787-789 |
|
| Persistence landscapes: Charting a path to unbiased radiological interpretation |
|
https://doi.org/10.18632/oncotarget.28671
Yashbir Singh, Colleen Farrelly, Quincy A. Hathaway, and Gunnar Carlsson
|
| 790-792 |
|
| Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists |
|
https://doi.org/10.18632/oncotarget.28672
Theia Minev, Shani Balbuena, Jaya Mini Gill, Francesco M. Marincola, Santosh Kesari, and Feng Lin
|
| 793-805 |
|
| Retraction: Hyperglycemia via activation of thromboxane A2 receptor impairs the integrity and function of blood-brain barrier in microvascular endothelial cells |
|
https://doi.org/10.18632/oncotarget.28675
Zhihong Zhao, Jue Hu, Xiaoping Gao, Hui Liang, Haiya Yu, Suosi Liu, and Zhan Liu
|
| 806-806 |
|
| B7-H4: A potential therapeutic target in adenoid cystic carcinoma |
|
https://doi.org/10.18632/oncotarget.28661
Luana Guimaraes de Sousa, and Renata Ferrarotto
|
| 807-808 |
|
| Computed tomography-based radiomics and body composition model for predicting hepatic decompensation |
|
https://doi.org/10.18632/oncotarget.28673
Yashbir Singh, John E. Eaton, Sudhakar K. Venkatesh, and Bradley J. Erickson
|
| 809-813 |
|
| Retraction: MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway |
|
https://doi.org/10.18632/oncotarget.28676
Xiao-Ping Wang, Jian Zhou, Ming Han, Chuan-Bao Chen, Yi-Tao Zheng, Xiao-Shun He, and Xiao-Peng Yuan
|
| 814-814 |
|
| Advancements in cell-penetrating monoclonal antibody treatment |
|
https://doi.org/10.18632/oncotarget.28674
Sai Pallavi Pradeep, and Raman Bahal
|
| 815-816 |
|
| Pitfalls and perils from FDA-approved germ-line cancer predisposition tests |
|
https://doi.org/10.18632/oncotarget.28677
Wafik S. El-Deiry, and Eli Y. Adashi
|
| 817-818 |
|
| Retraction: miR-133b inhibits glioma cell proliferation and invasion by targeting Sirt1 |
|
https://doi.org/10.18632/oncotarget.28678
Chuntao Li, Zhixiong Liu, Kui Yang, Xin Chen, Yu Zeng, Jinfang Liu, Zhenyan Li, and Yunsheng Liu
|
| 819-819 |
